The Vytorin controversy exposes shortcomings of surrogate endpoints

May 2008

The Vytorin controversy exposes shortcomings of surrogate endpoints.

Drugs are often approved, or used, based on their ability to change surrogate endpoints...blood pressure, lipids, serum glucose, etc.

These are often ASSUMED to reflect a drug's effectiveness.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote